Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,600 signal articles · 321 in last 24h · 112,439 total before filter · latest 20m ago
321last 24h
2139last 7d
381● bullish (7d)
186● bearish (7d)
204publishers
AllMacro299Earnings1210M&A91Regulatory22Product13Analyst20
✕ clear all filtersticker: PFEsentiment: bearishSentiment:bullishneutralbearishshow all (incl. clickbait)
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
Reuters28d agobearish
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.